IBM upgrade, Glaukos downgrade among today's top calls on Wall Street

Check out today's top analyst calls from around Wall Street, compiled by The Fly.

'MODEST' REVENUE GROWTH: Societe Generale analyst Richard Nguyen upgraded IBM (IBM) to Hold from Sell with a price target of $140, up from $121. The company could return to "modest" revenue growth, driven by a more active acquisition policy and a better mainframe cycle in 2022, Nguyen told investors in a research note. Further, the analyst argued that IBM's hybrid cloud focus continues to be underpinned by Red Hat and its CloudPaks offerings.

ISTENT REIMBURSEMENT CUTS: Wells Fargo analyst Lawrence Biegelsen downgraded Glaukos (GKOS) to Underweight from Equal Weight with a price target of $41, down from $100. The analyst sees downside risk to sales from the proposed reimbursement cuts to the company's iStent. The Centers for Medicare and Medicaid Services have issued the proposed outpatient prospective payment system for 2022, which includes the facility fees for the hospital outpatient and ambulatory surgery center settings. In the proposed rule, CMS lowered the facility fee in the ambulatory surgery center setting by 25% which was greater than expected, Biegelsen noted. This comes after the CMS cut the physician fee for the iStent by 90% in the proposed physician fee rule last week, the analyst added. He believes that if finalized, the proposed cuts are likely to have a "significant negative impact" on iStent sales.

MOVING TO THE SIDELINES: BTIG analyst Gray Powell downgraded Cloudflare (NET) to Neutral from Buy. The analyst cited valuation as the stock has recently run past his $103 per share price target, even though he still sees the company as a "long-term growth story." Powell added that he is not finding much evidence of momentum for Cloudflare in the SASE space as he had hoped to see at this point when it launched Teams last year, warning that its potential for growth could moderate as comps get tougher over the next few quarters.

To see the rest of the story Click Here.

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks